A stage-four cancer diagnosis once sounded like the end of the road – after all, there is no stage five. When Joe Biden’s prostate cancer was recently labelled “aggressive” and described ...

Two dual-payload antibody–drug conjugates are now in the clinic for cancer, with many more on the way.

ASCO 2025 has been a really busy meeting for breast cancer. We've seen data from SERENA-6, which has offered an intriguing and interesting way for us to be thinking about whether we've achieved ...

Woman Told She 'Didn't Qualify' for Testing After She Found Breast Lump. 10 Years Later, She's Battling Stage 4 Cancer "I have no choice just to get on with it and keep fighting," Leah Hughes said ...

AstraZeneca is jointly developing and commercializing ENHERTU, which is the drug being evaluated in the DESTINY-Endometrial01 phase 3 trial, with Daiichi Sankyo under a global collaboration.

The first patient has been dosed in the DESTINY-Endometrial01 phase 3 trial evaluating ENHERTU ® (trastuzumab deruxtecan) in combination with rilvegostomig or pembrolizumab versus platinum-based ...

Provided by Business WireJun 2, 2025, 12:00:00 PM ENHERTU® Plus Pertuzumab Reduced the Risk of Disease Progression or Death by 44% Versus THP as First-Line Therapy in Patients with HER2 Positive ...

ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab reduced the risk of disease progression or death by 44% vs. THP as 1st-line therapy in patients with HER2-positive metastatic breast ...

The cancer drug Enhertu stalled the growth of tumors by well over a year in a group of women with a type of metastatic but previously untreated breast cancer, a new study found.

Merck and Daaichi Sankyo pulled their Food and Drug Administration application for an experimental cancer drug. The drug failed in a late stage study. (Reuters) A new COVID-19 variant that has been ...